Scorpius(SCPX.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Scorpius
SCPX.US
Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities. It is also involved in the provision of various process development services, including upstream and downstream development and optimization, and analytical method development solutions, as well as cell line development, testing, and characterization services. The company serves the biotechnology and biopharmaceutical industries.
1.880 T
SCPX.USMarket value -Rank by Market Cap -/-

Financial Score

17/01/2026 Update
E
BiotechnologyIndustry
Industry Ranking391/398
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-296.72%E
    • Profit Margin-1424.30%E
    • Gross Margin-1221.07%E
  • Growth ScoreE
    • Revenue YoY-75.53%E
    • Net Profit YoY-7.78%C
    • Total Assets YoY-53.80%E
    • Net Assets YoY-136.23%E
  • Cash ScoreE
    • Cash Flow Margin-7.02%D
    • OCF YoY-75.53%E
  • Operating ScoreE
    • Turnover0.07E
  • Debt ScoreE
    • Gearing Ratio136.72%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Scorpius Holdings Signs Multiple Material Agreements

    Scorpius Holdings has signed four non-convertible promissory notes with an institutional investor, totaling approximately $239,539.77. Each note has a 5.0% annual interest rate and a 15% premium upon repayment, maturing between June and July 2026. The financing aims to enhance the company's liquidity and working capital flexibility. The agreements were signed on various dates from December 16, 2025, to January 8, 2026, with terms lasting until mid-2026.

    TradingView·
    US
    SCPX
    +733.33%
    TradingView·
    US
    SCPX
    +733.33%

    Scorpius Holdings Inc. Issues $44,375 Promissory Note at 5% Interest to Institutional Investor

    Scorpius Holdings Inc. has issued a $44,375 non-convertible promissory note to an institutional investor, with a 5% annual interest rate. The note matures on June 16, 2026, or upon a defined corporate event or default. Upon maturity, a 15% premium on the principal is required, along with accrued interest. The agreement includes default provisions and allows the noteholder to demand repayment from gross proceeds if Scorpius secures further financing while the note is outstanding.

    Reuters·
    US
    SCPX
    +733.33%
    Reuters·
    US
    SCPX
    +733.33%

    Scorpius Holdings reports Q2 revenue of USD 0.2 million, down 75 percent

    Scorpius Holdings Inc. reported Q2 revenue of USD 0.2 million, a 75% decline, and does not expect to generate revenue for the rest of 2025. The company's cost of revenues for Q2 was USD 0.2 million, with a total of USD 0.6 million for the first half of 2025. R&D expenses reached USD 6.0 million. The company has ceased operations, expressed doubt about its ability to continue, and is exploring options for capital needs, including equity and debt financing.

    Reuters·
    US
    SCPX
    +733.33%
    Reuters·
    US
    SCPX
    +733.33%

    Scorpius Holdings Extends Maturity of $2.25 Million Convertible Note to March 2026

    Scorpius Holdings Inc. has extended the maturity date of a $2.25 million convertible note held by Elusys Holdings Inc. from September 2025 to March 2026. The note may be converted into shares of common stock.

    Reuters·
    US
    SCPX
    +733.33%
    Reuters·
    US
    SCPX
    +733.33%

    Scorpius Holdings Delays Q3 Financial Report

    Scorpius Holdings Inc. has delayed filing its Q3 2025 Form 10-Q and previous reports for Q1 and Q2 2025. The company anticipates lower revenue and a higher net loss for the three and nine months ended September 30, 2025, compared to 2024. This information was disclosed via the U.S. SEC's EDGAR system.

    Reuters·
    US
    SCPX
    +733.33%
    Reuters·
    US
    SCPX
    +733.33%
    © 2026 Longbridge｜Disclaimer